Clinical trials: Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET)…
- Trial name
- PRRT-PARPi (NCT05870423)
- Testing
- olaparib
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Erasmus Medical Center
Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
This study is a phase 2, open, single-site trial. The primary objective of this study is to prospectively evaluate the safety and efficacy in participants treated with Lu-177 DOTATATE (Lutathera) in unresectable or metastatic…
- Conditions
- Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma, Those Requiring Repeat Peptide Receptor Radionuclide Therapy
- Trial name
- NCT06121271
- Testing
- Lu-177 DOTATATE (Lutathera®)
- Volunteers
- 110 people
- Sponsor
- University College, London
Neuroendocrine Tumors, Quality of Life
HRQoL During PRRT in Patients With NETs
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which may affect the patients' health-related quality of life (HRQoL).
- Conditions
- Neuroendocrine Tumors, Quality of Life, Peptide Receptor Radionuclide Therapy
- Trial name
- NCT05427032
- Volunteers
- 756 people
- Sponsor
- Uppsala University
Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT)
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)
The rationale behind the purpose of this study lays on: the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable…
- Trial name
- FENET-2016 (NCT04790708)
- Testing
- Lutetium-177 (177Lu)-DOTATOC, Yttrium-90 (90Y)-DOTATOC, 177Lu-DOTATOC + 90Y-DOTATOC
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University Hospital of Ferrara